US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE)

摘要 尼日利亚每年有大量可预防的癌症死亡。人乳头瘤病毒（HPV） 疫苗和B型肝炎（HBV）疫苗都是预防癌症的循证策略，但它们没有 在尼日利亚得到了广泛推广。这表明需要创新战略， 实施科学和挖掘集体智慧的尼日利亚，非洲人口最多的国家。我们提出 美国-尼日利亚癌症控制中心（US-Nigerian Cancer Control Center for Research on Implementation Science and Equity，C3-RISE）我们 总体使命有两个部分：（a）采用参与式实施科学战略（即众包开放 电话和学徒），以扩大HPV和HBV疫苗的摄取，以预防癌症;和（B）作为 在实施科学中促进公平和能力建设的中心，以促进对干预措施的理解 采用和维持循证干预措施，以预防癌症。该项目汇集了一个 来自尼日利亚医学研究所的多学科研究人员组成的一个特殊小组（ 联邦卫生研究组织，类似于美国NIH）、圣路易斯大学、北 查佩尔山的卡罗莱纳。我们提出以下目标：（1）通过以下方式加速公平的癌症控制： 制定、测试和完善参与性实施战略，以分散疫苗接种， （2）通过提供全面的信息，提高C3-RISE的科学生产力 业务和科学监督;（3）支持创新研究和学者的发展 在尼日利亚，培训人员加快采用和维持循证癌症控制干预措施。 这些目标将通过两个核心（行政、能力建设）的培育中心以及 两项研究（研究1关注HPV疫苗接种，研究2关注HBV疫苗接种）。我们的三个伙伴 四年前，一些机构发起了一个参与性的实施科学项目， 尼日利亚国家卫生准则，培训了231名学生，为43名教师提供了指导机会， 最后编写了世卫组织/贸易和发展报告关于众包促进健康的实用指南（UH 3 HD 096929）。这导致了最近 获得NCI R 01赠款（R 01-CA 271033），使用参与式实施科学开发创新 加强尼日利亚HPV服务的战略。C3-RISE将利用这一势头， 癌症研究、培训、社区参与和政策翻译。我们的项目将增加健康 公平，它与尼日利亚国家癌症控制计划保持一致，重点是参与，能力 建设和维护。这U 54赠款申请直接响应NIH，NCI和NIMH战略 优先事项

ABSTRACT Nigeria has a substantial number of preventable cancer deaths each year. The human papillomavirus (HPV) vaccine and hepatitis B (HBV) vaccine are both evidence-based strategies to prevent cancer, but they have not been widely scaled up in Nigeria. This suggests the need for innovative strategies that leverage implementation science and tap the collective wisdom of Nigeria, Africa’s most populous country. We propose the “US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE).” Our overall mission is two part: (a) use participatory implementation science strategies (i.e. crowdsourcing open calls and apprenticeships) to expand uptake of HPV and HBV vaccines for cancer prevention; and (b) serve as a hub for equity and capacity building in implementation science to advance the understanding of intervention uptake and sustainment of evidence-based interventions to prevent cancer. This project brings together an exceptional group of multi-disciplinary researchers from the Nigerian Institute of Medical Research (the apex federal health research organization, similar to the US NIH), St. Louis University, and the University of North Carolina at Chapel Hill. We propose the following aims: (1) To accelerate equitable cancer control by developing, testing, and refining participatory implementation strategies to decentralize vaccines to prevent cancer in community settings; (2) To enhance the scientific productivity of C3-RISE by providing overarching operational and scientific oversight; (3) To support innovative research and the development of scholars trained to accelerate the uptake and sustainment of evidence-based cancer control interventions in Nigeria. These aims will be accomplished by a nurturing hub of two cores (Administrative, Capacity Building) alongside two research studies (Study 1 focused on HPV vaccination, Study 2 on HBV vaccination). Our three partner institutions launched a participatory implementation science project four years ago that directly informed national Nigerian health guidelines, trained 231 students, provided mentorship opportunities to 43 faculty, and culminated in a WHO/TDR practical guide on crowdsourcing for health (UH3HD096929). This led to a recently awarded NCI R01 grant (R01-CA271033) that uses participatory implementation science to develop innovative strategies to enhance HPV services in Nigeria. C3-RISE will leverage this momentum to catalyze cutting-edge cancer research, training, community engagement, and policy translation. Our project will increase health equity, and it aligns with the Nigerian National Cancer Control Plan by focusing on participation, capacity building, and sustainment. This U54 grant application directly responds to NIH, NCI, and NIMH strategic priorities.